Nuclea Energy Signs Definitive Reverse Merger with Mangoceuticals, Existing Shareholders to Hold Just 4%
MGRX has more than doubled off its 52-week low of $0.162 on elevated volume (6.3× avg).
Summary
Nuclea Energy and Mangoceuticals have signed a definitive business combination agreement, advancing the reverse merger that will take the private nuclear startup public via Nasdaq. The deal gives Nuclea shareholders 96% of the combined company, leaving existing MGRX holders with just 4% — a massively dilutive outcome for current equity. The transaction is structured to close before stockholder and Nasdaq approvals, with a 19.99% cap on voting and economic rights until those approvals are secured. This follows the 8-K and 425 filings earlier today that first disclosed the planned merger, but the definitive agreement locks in terms and adds the unusual pre-approval closing mechanism. For a company with a going concern warning and a market cap under $7 million, the reverse merger represents a complete transformation into a nuclear energy play, though existing shareholders are nearly wiped out. The deal positions Nuclea to fund its Morpheus microreactor development amid surging AI-driven electricity demand.
At the time of this announcement, MGRX was trading at $0.38 on NASDAQ in the Energy & Transportation sector, with a market capitalization of approximately $6.5M. The 52-week trading range was $0.16 to $2.75. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: TMX Newsfile.